← The Wire·Breaking·Regulation··2 outlets

Beta Bionics wins FDA clearance for Mint patch insulin pump

Beta Bionics announced FDA clearance of Mint, a reusable-and-disposable insulin-delivery patch pump with CGM integration and smartphone control. The clearance gives BBNX a new commercial product and a potential route to expand beyond its existing insulin-delivery market.

STOCK PHOTO · VLAD VASNETSOV

The story

Beta Bionics announced on Sept. 14 that the U.S. Food and Drug Administration had cleared Mint, its patch pump for insulin delivery. The company described a reusable-and-disposable architecture that does not require recharging, works with industry-leading continuous glucose monitors and supports control through iOS and Android smartphones.

The clearance adds a second product development milestone to the announcement: Beta Bionics also unveiled 3D Intelligence, which it called its next-generation insulin-dosing algorithm.

The product is intended to connect several parts of the diabetes-management stack. Mint's pump hardware handles insulin delivery, CGM integration supplies glucose data, and smartphone control provides the user interface; the company said the combination could meaningfully expand its addressable insulin-delivery market, particularly among users seeking a patch-pump format.

The next concrete markers are Beta Bionics' launch plans and commercial availability. The company's FY 2025 revenue was $100.3 million, up 53.9% year over year, while net margin was -73.0%; those figures set a high bar for Mint to convert regulatory clearance into sustainable growth and profitability.

Our read · Mon, Sep 14

FDA cleared Beta Bionics’ Mint insulin-delivery patch pump, giving BBNX a commercial product with CGM integration and smartphone control.

Why. The clearance removes a regulatory gate for a product designed to broaden Beta Bionics’ insulin-delivery market, making commercialization the next value driver. BBNX’s FY 2025 revenue grew 53.9% to $100.3 million, but its -73.0% net margin means the read depends on whether Mint gains adoption without extending the path to profitability.

Both cases

The case it holdsFDA clearance creates a concrete product catalyst on top of FY 2025 revenue growth of 53.9%, while Mint’s CGM integration and smartphone control could widen Beta Bionics’ addressable market.
The case it breaksThe announcement gives no launch date, pricing, reimbursement terms or financial targets, and the company’s FY 2025 net margin was -73.0%, leaving commercialization and cash needs as material unresolved risks.

What could change this view: The trade fails if Beta Bionics delays commercial availability, cannot secure reimbursement or manufacturing scale, or if Mint’s launch costs deepen losses without a measurable revenue contribution.

Beta Bionics stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 2

Keep reading

Latest on the Wire

Iran claims strikes on two US bases in Bahrain as Trump line is testedTrump calls Russian missiles in Poland mistakes before fresh incursionAmazon nears $7.5bn Decart deal as AWS takes on Nvidia in AI computingRussian cargo ship Sparta II reportedly hit by drones near FinlandBTCS warns $54 million Aave loan faces liquidation as ether fallsContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on Thursday
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by GlobeNewswire as Beta Bionics Announces FDA Clearance of Mint™, the Company’s Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm, . Who answers for this

2 reports from 1 publisher in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →